The incidence of skin and soft tissue infections in the United States and associated health care utilization between 2010 and 2020

Abstract

Abstract Background The number of patients with skin and soft tissue infections (SSTI) in the United States appeared to be increasing well into the 21st century. However, no recent data have confirmed this trend. Methods This retrospective, observational cohort study used claims data over 11 years (2010–2020) from Optum’s de-identified Clinformatics® Data Mart Database. SSTI episodes, complications, and comorbidities were identified using International Classification of Disease codes. Annual SSTI incidence rates, proportions of recurrent SSTI, SSTI-associated deaths, and total costs were estimated. Results During the study period, 5.4 million patients experienced 9.1 million SSTI episodes, with an incidence of 77.5 per 1000 person-years of observation (PYO) (95% confidence interval [CI] 77.4–77.5). Annual incidence did not change significantly over time. Overall incidence (per 1000 PYO) of SSTI episodes in patients without comorbidities was 32.1 (highest incidence was for previous SSTI (113.5)) versus much higher rates if comorbidities were present. Incidence rates (per 1000 PYO) of chronic ulcers increased over time from 11.3 to 18.2 (p < 0.0001) and complicated disease from 3.5 to 6.3 (p < 0.0001). Deaths occurring within 30 days post-SSTI hospitalization rose from 2.6% to 4.6% in 2020. Recurrences occurred in 26.3% of index cases. The mean cost of an SSTI episode was $3334 (median $190) and was highest for surgical site infections and chronic ulcers. Conclusions The epidemiology of SSTI in the US is changing and the disease burden is increasing despite stabilization in overall incidence. These data can inform identification of priority populations who could benefit from targeted interventions.